Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced the presentation ...

Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development for Multiple ... Read More The post Alterity in spotlight at medical ...

SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in ...

The buildup of a protein called 𝛂-synuclein (ASN) into toxic clumps is a hallmark of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson's and multiple system atrophy ...

Provided to chinadaily.com.cn] After around a decade of persistent efforts, scientists in Shanghai have developed a ...

The Mount Sinai Health System is opening the Carolyn Rowan Center for Women's Health and Wellness, a transformative new model for women's health that brings together multidisciplinary clinical ...

Alzheimer’s doesn’t begin with memory loss. It starts decades earlier. New research reveals that a simple trace mineral may ...

A new study led by researchers at the University of California San Diego School of Medicine suggests that an experimental ...

Summary: Researchers demonstrated that an experimental, systemic gene therapy can shield the central nervous system from the devastating cognitive decline and structural damage caused by ...

A new study offers clues as to why exercise can improve neurological symptoms in people with multiple sclerosis (MS).

A 71-year-old with a vitamin B12 reading that looks perfectly fine on paper might still be losing ground inside the brain.

The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake. For a ...